Search Within

Kuo-Kai Chin

Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (9)
  2. Department of Medicine (9)
  3. GME, Medicine (9)
  4. Graduate Medical Education (9)
  5. Hematologic Malignancies, Division of (9)
  6. Hematology-Oncology Fellows (9)

More Groups

People
  1. Eytan Stein (8)
  2. Christopher Famulare (7)
  3. Andriy Derkach (5)
  4. Jae Park (5)
  5. Ioannis Kalogirou Valtis (4)
  6. Leora Boussi (4)

More People

Years
  1. 2025 (4)
  2. 2024 (4)
  3. 2023 (1)
Publications
  1. Blood (5)
  2. Blood Advances (2)
  3. JAMA Oncology (1)
  4. Leukemia and Lymphoma (1)
Publishers
  1. American Society of Hematology (7)
  2. American Medical Association (1)
  3. Taylor & Francis Group (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction
    Journal Article

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Barriers to chimeric antigen receptor T-cell therapy
    Research Letter

    Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: A multicenter real-world analysis
    Journal Article

    Pidala, J.; Kim, J.; Kalos, D.; Cutler, C.; DeFilipp, Z.; Flowers, M. E. D.; Hamilton, B. K.; Chin, K. K.; Rotta, M.; El Jurdi, N.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase II study of the menin inhibitor revumenib in leukemia associated with upregulation of HOX genes: Trial in progress
    Meeting Abstract

    Issa, G. C.; Chin, K. K.; Blachly, J. S.; Farhat, A.; Xiao, L.; Ning, J.; Cuglievan, B.; Shukla, N.; Sasaki, K.; Loghavi, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
    Meeting Abstract

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save